Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07741929

Patient and Provider Perspectives on Genetic Risk Profiling

Patient and Provider Perspectives on Genetic Risk Profiling — Recruiting • Oncology • NCT07741929.

📅 03 Aug 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07741929
Sponsor
Royal Marsden NHS Foundation Trust
Start
2026-05-01
ClinicaliQ Trial Snapshot
  • Patient and Provider Perspectives on Genetic Risk Profiling — Recruiting • Oncology • NCT07741929.
  • What is being tested: Patient and healthcare provider perspectives on the clinical utility and practical application of genetic risk profiling when integrated into routine clinical practice, explored through qualitative interviews.
  • Patient eligibility overview: The study recruits patients who have undergone or are eligible for genetic risk profiling, alongside healthcare providers involved in delivering or interpreting genetic risk assessments in clinical settings.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

A qualitative interview study exploring the patient and provider perspectives on the clinical utility of genetic risk profiling in routine clinical practice. The findings from the study may contribute towards future research and informing clinical practice.

Eligibility Snapshot
  • : * Individuals assigned male at birth who are aged 18 and over and who have capacity to consent * Patients who have undergone genetic risk profiling for prostate cancer and have received their results * Individuals from diverse backgrounds (age, ethnicity, risk status, etc) * Healthcare providers who have delivered a genetic risk profiling result for prostate cancer

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Breast cancer checks missing most women under 50 who are at risk, says study
Oncology · BBC Health · 04 Aug 2026
Current NHS breast screening programmes fail to identify approximately 95% of women under 50 at higher genetic or familial risk of breast…
View brief →
Guideline
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
Oncology · 19 Aug 2026
First-line treatment option: Acalabrutinib combined with bendamustine and rituximab is recommended as a first-line treatment for untreated mantle cell lymphoma, offering an…
View guideline →
Guideline
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)
Oncology · 16 Jul 2026
Evaluation terminated – NICE discontinued appraisal of lutetium-177 vipivotide tetraxetan; this agent is not recommended for routine NHS use and should not…
View guideline →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia
Oncology · 19 Aug 2026
Use acalabrutinib with venetoclax ± obinutuzumab as first-line treatment for untreated CLL – this combination is recommended by NICE and offers improved…
View guideline →
Guideline
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer
Oncology · 14 Jul 2026
Pembrolizumab combined with chemoradiotherapy is recommended for untreated locally advanced cervical cancer, improving survival outcomes compared to chemoradiotherapy alone—consider this combination as…
View guideline →